Evaluation of structural-functional changes of the left ventricular myocardium in patients with arterial hypertension and obesity by the level of irisin

Authors

  • O. V. Shaparenko Kharkiv National Medical University, Ukraine,
  • P. H. Kravchun Kharkiv National Medical University, Ukraine,
  • P. P. Kravchun Kharkiv National Medical University, Ukraine,
  • O. I. Kadykova Kharkiv National Medical University, Ukraine,
  • H. V. Lisova Kharkiv National Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2019.1.155783

Keywords:

hypertension, obesity, irisin, haemodynamics

Abstract

The aim was to evaluate the structural and functional changes of the left ventricular myocardium according to the data of echocardiography in patients with arterial hypertension combined with obesity by the level of irisin.

Materials and methods. 105 patients were divided into 2 groups for participation in the study: the 1 group consisted of patients with arterial hypertension with concomitant obesity with concomitant obesity (n = 70), the group 2 – patients with arterial hypertension and normal body weight (n = 35). The control group consisted of 25 practically healthy persons. All participants of the study underwent irisin level measurement by an enzyme-linked immuno-sorbent assay and an echocardiographic examination with subsequent computer processing of the results using the software package “Statistica 6.0” (StatSoft Inc.,USA).

Results. In patients with arterial hypertension and obesity, hypoirisinemia (irisin level <1.19 ± 0.03 ng/ml) was associated with an increase in the end-diastolic and systolic volumes by 31.57 % (r = -0.44; Р < 0. 05) and 20.70 % (r = -0.53; P <0.05), sizes – by 43.54 % (r = -0.36; P < 0.05) and 40.44 % (r = -0.62; P < 0.05) and decrease in the ejection fraction by 16.59 % (r = 0.41; P < 0.05) (P < 0.05).

Conclusions. Decrease in the content of serum irisin leads to structural and functional changes in the left ventricular myocardium in the form of myocardial contractility reduction and increase in both the cavity and size of the left ventricle, and can play a role in the pathogenesis of obesity in patients with arterial hypertension.

References

Kovalenko, V. M., Kornatskyi, V. M., et al. (2014). Khvoroby systemy krovoobihu yak medyko-sotsialna i suspilno-politychna problema [Diseases of the circulatory system as a medical and social and socio-political problem]. Kyiv. [in Ukrainian].

Roca-Rivada, A., Castelao, C., Senin, L. L., Landrove, M. O., Baltar, J., Belén Crujeiras, A., et al. (2013). FNDC5/irisin is not only a myokine but also an adipokine. PLoS One, 8(4), e60563. doi: 10.1371/journal.pone.0060563.

Moreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones F., et al. (2013). Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J. Clin. Endocrinol. Metab., 98(4), E769–E778. doi: 10.1210/jc.2012-2749.

Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., et al. (2012). A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463–8. doi: 10.1038/nature10777.

Stanford, K. I., Middelbeek, R. J., Townsend, K. L., An, D., Nygaard, E. B., Hitchcox, K. M, et al. (2013). Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest., 123(1), 215–23. doi: 10.1172/JCI62308.

Belviranli, M., Okudan, N., & Çelik F. (2016). Association of Circulating Irisin with Insulin Resistance and Oxidative Stress in Obese Women. Horm. Metab. Res., 48(10), 653–657. doi: 10.1055/s-0042-116155.

Kurdiova, T., Balaz, M., Vician, M., Maderova, D., Vlcek, M., Valkovic, L., et al. (2014). Effects of obesity, diabetes and exercise on FNDC5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J. Physiol., 592(5), 1091–107. doi: 10.1113/jphysiol.2013.264655.

Liu, J. J., Wong, M. D., Toy, W. C., Tan, C. S., Liu, S., Ng, X. W., et al. (2013). Lower circulating irisin is associated with type 2 diabetes mellitus. J. Diabetes Complications, 27(4), 365–9. doi: 10.1016/j.jdiacomp.2013.03.002.

Sanchis‐Gomar, F., & Perez‐Quilis, C. (2014). The p38‐PGC‐1α‐irisin‐betatrophin axis: exploring new pathways in insulin resistance. Adipocyte, 3(1), 67–8. doi: 10.4161/adip.27370.

Park, S. E., Park, C. Y., & Sweeney, G. (2015). Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit. Rev. Clin. Lab. Sci., 52(4), 180–90. doi: 10.3109/10408363.2015.1023429.

Aronis, K. N., Moreno, M., Polyzos, S. A., Moreno-Navarrete, J. M., Ricart, W., Delgado, E., et al. (2015). Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes (Lond), 39(1), 156–61. doi: 10.1038/ijo.2014.101.

Kuloglu, T., Aydin, S., Eren, M. N., , Yilmaz, M., Sahin, I., Kalayci, M., et al. (2014). Irisin: a potentially candidate marker for myocardial infarction. Peptides, 55, 85–91. doi: 10.1016/j.peptides.2014.02.008

Downloads

How to Cite

1.
Shaparenko OV, Kravchun PH, Kravchun PP, Kadykova OI, Lisova HV. Evaluation of structural-functional changes of the left ventricular myocardium in patients with arterial hypertension and obesity by the level of irisin. Zaporozhye medical journal [Internet]. 2019Feb.8 [cited 2024Feb.24];(1). Available from: http://zmj.zsmu.edu.ua/article/view/155783

Issue

Section

Original research